Open AccessDeveloping Exposure/Response Models for Anticancer Drug Treatment: Special Considerations
Author(s) -
Mould DR,
Walz AC,
Lave T,
Gibbs JP,
Frame B
Publication year - 2015
Publication title -
cpt: pharmacometrics and systems pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 37
ISSN - 2163-8306
DOI - 10.1002/psp4.16
Subject(s) - dosing , drug , clinical pharmacology , medicine , pharmacology , anticancer drug , drug development , intensive care medicine
Anticancer agents often have a narrow therapeutic index (TI), requiring precise dosing to ensure sufficient exposure for clinical activity while minimizing toxicity. These agents frequently have complex pharmacology, and combination therapy may cause schedule‐specific effects and interactions. We review anticancer drug development, showing how integration of modeling and simulation throughout development can inform anticancer dose selection, potentially improving the late‐phase success rate. This article has a companion article in Clinical Pharmacology & Therapeutics with practical examples. CPT Pharmacometrics Syst. Pharmacol. (2015) 4, 12–27; doi: 10.1002/psp4.16 ; published online 21 January 2015